KRX Growth Companies With High Insider Ownership Growing Earnings Up To 99%

Simply Wall St · 10/15 05:35

The South Korean market has recently been in the spotlight due to cultural achievements, such as Han Kang's Nobel Prize win, which underscores the nation's growing influence on the global stage. In this thriving environment, growth companies with high insider ownership are particularly appealing as they often signal strong confidence from those who know the business best and can lead to substantial earnings growth.

Top 10 Growth Companies With High Insider Ownership In South Korea

Name Insider Ownership Earnings Growth
People & Technology (KOSDAQ:A137400) 16.4% 35.6%
Seojin SystemLtd (KOSDAQ:A178320) 30.8% 49.1%
Bioneer (KOSDAQ:A064550) 15.8% 97.6%
Oscotec (KOSDAQ:A039200) 26.1% 122%
HANA Micron (KOSDAQ:A067310) 18.3% 105.8%
Park Systems (KOSDAQ:A140860) 33% 34.6%
Vuno (KOSDAQ:A338220) 19.4% 110.9%
UTI (KOSDAQ:A179900) 33.1% 134.6%
Techwing (KOSDAQ:A089030) 18.7% 83.6%
INTEKPLUS (KOSDAQ:A064290) 16.3% 96.7%

Click here to see the full list of 86 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩20.11 trillion.

Operations: The company's revenue primarily stems from its biotechnology segment, which generated ₩90.79 billion.

Insider Ownership: 26.6%

Earnings Growth Forecast: 99.5% p.a.

ALTEOGEN is forecast to achieve significant growth, with expected annual revenue increases of 64.2%, outpacing the KR market's 10.4%. Profitability is anticipated within three years, marking above-average market growth. The company's Return on Equity is projected to be very high at 66.3% in three years. Despite trading at 71% below its estimated fair value, shareholders have faced dilution over the past year, and there has been no substantial insider trading activity recently.

KOSDAQ:A196170 Ownership Breakdown as at Oct 2024
KOSDAQ:A196170 Ownership Breakdown as at Oct 2024

ABL Bio (KOSDAQ:A298380)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc. is a biotech research company that develops therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩1.99 trillion.

Operations: The company's revenue segment is primarily derived from biotechnology startups, amounting to ₩32.95 billion.

Insider Ownership: 30.5%

Earnings Growth Forecast: 48.2% p.a.

ABL Bio is positioned for robust growth, with revenue projected to increase by 24.7% annually, surpassing the South Korean market's average. The company is expected to achieve profitability within three years, indicating above-average market growth potential. However, its Return on Equity is forecasted to be relatively low at 13% in three years. Despite recent share price volatility and no significant insider trading activity reported in the past three months, ABL Bio remains a key contender in its sector.

KOSDAQ:A298380 Earnings and Revenue Growth as at Oct 2024
KOSDAQ:A298380 Earnings and Revenue Growth as at Oct 2024

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. operates in music production, publishing, and artist development and management, with a market cap of approximately ₩7.68 trillion.

Operations: The company's revenue is derived from three main segments: Label (₩1.28 trillion), Platform (₩361.12 billion), and Solution (₩1.24 trillion).

Insider Ownership: 32.5%

Earnings Growth Forecast: 42.6% p.a.

HYBE demonstrates strong growth potential with earnings expected to grow significantly at 42.6% annually, outpacing the South Korean market average. Despite recent one-off items affecting financial results, the company is trading below its estimated fair value by 22%. HYBE completed a share buyback program for KRW 26.09 billion to stabilize stock prices. However, recent earnings showed a decline in net income and basic earnings per share compared to last year’s figures.

KOSE:A352820 Earnings and Revenue Growth as at Oct 2024
KOSE:A352820 Earnings and Revenue Growth as at Oct 2024

Taking Advantage

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.